https://www.selleckchem.com/products/Nolvadex.html
26; 95% CI=0.08-0.83; p0.05) compared to other TCM use. In contrast, using TCM (either short-term or long-term) was not associated with MPR in HT. Our results supported the potential advantage of TCM on breast cancer-associated mortality, whereas TCM use does not compromise medical adherence to HT. This study offers important insights in integrative therapy for HT in patients with estrogen receptor (+) breast cancer. Our results supported the potential advantage of TCM on breast cancer-associated mortality, whereas TCM use does not
Like
Comment
Share
